Genitourinary Cancer Disease Management Group Research
At Perlmutter Cancer Center, the Genitourinary Cancer Disease Management Group (DMG) provides coordinated, multidisciplinary expertise from urologists, medical oncologists, and radiation oncologists who treat prostate, kidney, bladder, and testicular cancers. In the laboratory and the clinic, our researchers collaborate to decipher the mechanisms of cancer carcinogenesis; develop new methods for diagnosing and treating genitourinary cancers; implement clinical trials; and provide optimal and personalized multidisciplinary treatment through the Smilow Comprehensive Prostate Cancer Center.
Our research focuses on novel immunotherapies, targeted therapies, and combinations of treatments for genitourinary cancers.
Genitourinary Cancer Research Leadership
Arjun V. Balar, MD
Director, Genitourinary Medical Oncology Program
Assistant Professor, Department of Medicine
Samir Taneja, MD
Genitourologic Program Leader
Co-Director, Smilow Comprehensive Prostate Cancer Center
The James M. Neissa and Janet Riha Neissa Associate Professor of Urologic Oncology, Department of Urology
Andrew J. Evans, MD
Clinical Associate Professor, Department of Radiation Oncology
Medical Director, Department of Radiation Oncology
Vice Chair of Clinical Operations, Department of Radiation Oncology
Prostate Cancer Research Areas of Focus
Our scientists and clinicians focus on improving screening, diagnosis, and staging or grading prostate cancer using multiparametric MRI, which follows a set of protocols to visualize the prostate gland, providing information on the value of biopsy.
Bladder Cancer Research Areas of Focus
Our investigators develop novel immunotherapies for high-grade and advanced bladder and renal cancers. Our phase II studies of the immunotherapy drug atezolizumab and pembrolizumab, an anti-PD1 drug, in advanced bladder cancer led to accelerated approval for both treatments by the U.S. Food and Drug Administration (FDA). These are the first-ever and only FDA-approved medications for cisplatin-ineligible patients with advanced urothelial cancer.